Peptide Stack

What it does

BPC-157 is a 15-amino-acid peptide derived from a protein naturally found in gastric juice. It was identified as a body protection compound because of its remarkable ability to accelerate healing in damaged tissue — tendons, ligaments, muscle, gut lining, blood vessels, and bone. In this protocol, it's being used specifically for its angiogenic and tendon repair properties at the left ankle/Achilles wound site.

Mechanism of action

BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2) — the primary signaling receptor for new blood vessel formation. This is the key mechanism for a wound that isn't healing because of poor circulation. No blood flow to the wound = no healing. BPC-157 directly stimulates angiogenesis (the growth of new capillaries) into tissue that has been deprived of adequate circulation.

It also activates the FAK-paxillin pathway, which drives tendon cell proliferation and migration into injured tissue. The Achilles has been compromised since 1986 — this pathway targets the collagen matrix of the tendon directly. Additionally, BPC-157 modulates nitric oxide production, further supporting blood flow to the damaged area.

Why subcutaneous near the navel

BPC-157 is injected subcutaneously (into belly fat) rather than intramuscularly or directly into the wound site. Subcutaneous injection provides a slow, sustained release into the bloodstream. Because BPC-157 is systemic in its uptake, it reaches the ankle wound through circulation — and since we're simultaneously driving angiogenesis to build new capillary pathways, the peptide can reach the site even where blood flow is currently poor. Rotating injection sites (left/right of navel) prevents localized irritation.

Why it matters for this case

DVT in both legs means active blood clots restricting venous return. Neuropathy in both legs means the nerves supplying the ankle have been damaged. The left ankle wound has not healed because the tissue is under-perfused — not enough blood carrying oxygen, nutrients, and immune cells to the repair site. BPC-157 addresses this directly by building the vascular infrastructure the healing process requires. It doesn't mask pain or reduce inflammation as a side effect — it goes after the root cause.

What it does

TB-500 is a synthetic version of a fragment of Thymosin Beta-4, a naturally occurring peptide found in high concentrations at wound sites throughout the body. While BPC-157 works locally — concentrating its repair effects near the injection site — TB-500 is highly systemic. It travels throughout the body, promoting repair wherever tissue has been damaged. In a case involving DVT, neuropathy, and a chronic wound, this systemic reach is critical.

Mechanism of action

TB-500's primary mechanism is actin sequestration. Actin is the protein that forms the cellular skeleton and drives cell movement. By binding to actin, TB-500 promotes the migration of endothelial cells (which line blood vessels), keratinocytes (skin cells), and fibroblasts (connective tissue cells) into damaged areas. This is how wounds close and how new tissue is laid down.

TB-500 also downregulates inflammatory cytokines while upregulating growth factors including VEGF (vascular endothelial growth factor). It reduces scar tissue formation and promotes flexibility in repaired tissue — important for the Achilles tendon, which needs to flex without tearing. For the neuropathy: TB-500 has shown nerve regeneration properties in animal models, promoting remyelination of damaged nerve fibers.

Loading phase vs. maintenance

Weeks 1–4 are the loading phase: 2.5mg twice weekly. The goal is to saturate the system and drive acute repair. After 4 weeks, the protocol drops to once weekly maintenance — enough to sustain the repair environment without over-stimulating it. The loading phase is where the most significant initial changes should occur; the maintenance phase locks in the gains. Reorder TB-500 around September 2, 2026 to avoid a gap into maintenance.